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Synopsis:  
This study uses “big data” to assess outcomes of patients attending a virtual glaucoma 
monitoring service. The findings suggest this new model of service delivery is a viable 
means of monitoring low-risk glaucoma patients. 
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Abstract 
Aim: To assess the equivalence of measurement outcomes between patients attending a 
standard glaucoma care service, where patients see an ophthalmologist in a face-to-face 
setting, and a glaucoma monitoring service (GMS). 
Methods: The average mean deviation (MD) measurement on the visual field (VF) test 
for 250 patients attending a GMS were compared to a “big data” repository of patients 
attending a standard glaucoma care service (reference database). In addition, the speed 
of VF progression between GMS patients and reference database patients were 
compared. Reference database patients were used to create expected outcomes that GMS 
patients could be compared to. For GMS patients falling outside of the expected limits, 
further analysis was carried out on the clinical management decisions for these patients. 
Results: The average MD of patients in the GMS ranged from +1.6 dB to -18.9 dB between 
two consecutive appointments at the clinic. In the first analysis, twelve (4.8%; 95% 
confidence interval [CI] 2.5 to 8.2%) GMS patients scored outside the 90% expected 
values based on the reference database. In the second analysis, 1.9% (95% CI 0.4 to 5.4 
%) GMS patients had VF changes outside of expected 90% limits.  
Conclusions: Using “big data” collected in the standard glaucoma care service, we found 
that patients attending a GMS have equivalent outcomes on the VF test. Our findings 
provide support for the implementation of virtual healthcare delivery in the hospital eye 
service (HES). 
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Introduction 
The United Kingdom (UK) National Health Service (NHS) is facing unprecedented 
challenges. Although overall life expectancy is increasing, with it comes a greater 
prevalence of disease in the population, (1) and chronic disease management remains a 
significant burden on the NHS. (2) There is a need for the NHS to redesign its services to 
make a more efficient healthcare service provider.  
A drive exists for the NHS to make more use of information technology (IT). (3) 
One such example is the development of virtual clinics, which remove the face-to-face 
doctor-patient consultation.  Within the hospital eye service (HES), virtual clinics have 
not only been found to provide valuable additional out-patient capacity, but can also 
streamline referral rates, reduce costs, and improve the patients’ health care experience. 
(4-7) Improvements in disease detection by primary eye care service providers have 
meant that the HES has become one of the busiest health care providers in the UK. (8-11) 
As a result, the introduction of new methods to assist with the monitoring of patients with 
chronic ocular disease in the HES is a high priority.  
Virtual clinics offer a viable means of monitoring glaucoma patients. (5, 12-14) To 
date, most studies have focused on the accuracy of disease staging, as well as patient 
satisfaction, cost reduction, and appointment durations. (4, 14-15) An important safety 
aspect of virtual clinics is whether disease progression can be identified and acted on 
effectively. By doing so, scrutiny can be placed on the extent to which virtual clinic 
patients differ from patients in consultant-led appointments when performing the same 
tests. This type of analysis can be conducted through an audit-style assessment using 
large scale data.  
 Following the development and expansion of the Internet, as well as the advent of 
new and innovative technologies, the use of large scale data, or “big data”, has increased 
dramatically in recent years. (16) Put simply, large databases from routine services can 
be used to compare individual or population results of patients attending a single 
hospital, practice, or clinic. This method has been used recently in the field of 
ophthalmology. (17-18)  
A virtual clinic must be effective at identifying patients who have become unstable 
and are in need of closer observation. One method to assess this aspect of virtual clinics 
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is to use large scale data collected from consultant-led appointments as benchmarks for 
patient’s measurement results. This is the idea explored in this current work. 
In this study, we examine the effectiveness of a virtual glaucoma monitoring 
service (GMS) at identifying unstable patients requiring closer observation. In addition, 
we assess whether “big data” analysis can be used to identify patients achieving visual 
field (VF) test scores outside of the expected range. 
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Materials and methods 
 Following authorisation from the Caldicott Guardian and Information Governance 
Lead at Moorfields Eye Hospital NHS Foundation Trust (MEH), anonymised VF results 
from the Humphrey Field Analyser (HFA; Carl-Zeiss Meditec, Dublin, CA, USA) of patients 
attending the glaucoma monitoring service (GMS) were analysed. The GMS, and criteria 
for patient inclusion into the service, is described in a previous publication from our 
group. (4) In brief, clinical examinations of ‘early’ and ‘moderate’ disease stage glaucoma 
patients are carried out by trained ophthalmic technicians and data are reviewed by two 
consultants and a senior glaucoma specialist optometrist on a different day for clinical 
management decisions. (4) 
Data from VFs were extracted with the optical character recognition function 
using a purpose-written program authored in MatLab 2016b (Mathworks Inc.). Data 
were restricted to patient’s age, test date, test eye, test reliability, and mean deviation 
(MD). The latter is conventionally used in clinics; it is a summary measure of the overall 
reduction in VF sensitivity relative to a group of healthy age-matched observers, with 
more negative values indicating a worse VF. We used patients’ worse eye (based on MD) 
at their first GMS visit as our study eye. 
Inclusion criteria required patients to have at least two visits to the GMS no less 
than 4 months apart. The first 250 patients who entered the GMS since its start in 2014 
who fulfilled this criterion were analysed. This sample represents approximately 15% of 
patients attending the GMS at the time of data collection.  
Data Analysis 
We used the difference in MD between GMS patients’ baseline and second 
appointment as a surrogate of VF stability. Large differences would suggest a change in 
the VF, or poor repeatability.  
Limits were defined for change in MD from a database of 473,252 VF records (the 
reference database). These data are described elsewhere (19) and were pooled from 
88,954 patients from four centres in the United Kingdom: Moorfields Eye Hospital NHS 
Foundation Trust, London; Cheltenham General Hospital Gloucestershire Eye Unit; 
Queen Alexandra Hospital, Portsmouth; and the Calderdale and Huddersfield NHS 
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Foundation Trust. Only patients tested using the 24-2 testing algorithm were included, 
resulting in a total of 83,794 patients. 
Patients attending the GMS are all experienced in perimetry, but this may not 
necessarily be true for patients within the reference database. Thus, we excluded the first 
ever VF test for patients within the reference database to allow for perimetric 'learning'. 
Furthermore, eliminating the first visual field in a patient's series would also exclude 
patients from the reference database who had a single, exploratory VF, thereby increasing 
the confidence that patients remaining in the reference database who had at least 2 
subsequent VFs were being monitored for glaucoma. In this database, 41,048 patients 
(49%) were excluded based on this criterion. In addition, we restricted the age (minimum 
age of 20 years) for the reference database to ensure that these patients were age-related 
to patients seen in the GMS. Duration between appointments in the reference database 
was restricted to between 4 and 24 months to ensure similar time intervals for follow up 
between the two groups. After applying these criteria, 22,124 patients remained in the 
reference database. We then grouped the average MDs by VF defect severity using bins 
of 1dB width. We did this because VF measurement repeatability is strongly associated 
with VF severity. (20) The 5th, 25th, 75th and 95th percentile of the distribution of 
difference were then derived and plotted. Points were connected using a locally weighted 
smoothing operator (LOESS) to create a colour coded chart for the 50% and 90% limits 
of change for MD in the reference database (See figure 1).  We would, for example, expect 
10% of GMS patients to have repeat MD differences outside of the latter limits. By using 
this method, GMS patients who had VF results that were markedly different to those in 
the reference database (i.e. outside the 90% normal limit) could be identified. 
For the second part of the analysis, we included a subset of the GMS patients who 
had attended three or more appointments (N=158). GMS patients with three VFs were 
compared to patients in the reference database with three VFs; this was repeated for 
patients with four and five VFs. Where two VFs were conducted within 4 months, the 
patients’ next measurement in their VF series within our inclusion criteria was used. 
Simple linear regression was used to calculate the rate of VF progression (MD dB loss per 
year). Regression lines for the reference database were plotted using a novel data 
visualisation tool, the Hedgehog Plot. This tool allows us to visualise the progression rates 
for all patients simultaneously. The reference database was used to determine the 90% 
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limits by computing the 5th and 95th percentiles of the estimated slopes. The regression 
lines for the GMS patients were then superimposed onto the Hedgehog plot and eyes 
which were found to be outside of the calculated limits were flagged.  
The clinical management decisions for all 250 GMS patients at the time of their 
most recent field were also collected. All statistical analysis was done in R (www.R-
project.org). 
 
Results 
Median (interquartile range; IQR) age of GMS patients at first visit was 65 (54, 72) 
years. Median (IQR) MD for GMS patients’ worse eye at baseline was -1.5 (-3.1, -0.3) dB. 
Median (IQR) number of months between the first and second GMS clinic appointments 
was 12 (10, 12) ranging from 4 months to 21 months. Average MD of the first and second 
appointments of the 250 GMS patients ranged between +1.6 dB and -18.9 dB (median -
1.4 (-3.0, -0.4) dB). Median (IQR) age of patients from the reference database was 67 (57, 
76) years. 
Of the 250 GMS patients, 12 (4.8%; 95% confidence interval [CI] 2.5 to 8.2%)) 
recorded values outside the 90% limits. This proportion was less than the expected value 
of 10% and was statistically significant (p = 0.003). (A post-hoc power calculation 
confirms our study to have had an adequate sample size. A total of 4.8% outside the 90% 
limit returns a power (beta) value of 0.86 when alpha is set at 0.05 and N = 250; Minitab 
17 Statistical Software (2010); www.minitab.com). 
Figure 2 shows the results of the GMS patients (points) compared to the reference 
database. We split the GMS patients into three equally sized groups. Plot A ranges from -
18.9 dB to ≤ -2.4 dB (83 GMS patients), plot B ranges from > -2.4 dB to ≤-0.8 dB (84 GMS 
patients), and plot C includes patients > -0.8 dB (83 GMS patients). 
Figure 3 shows the rate of VF progression for patients in the reference database. 
Each line represents an eye, with the length of the line indicating the length of follow-up. 
The location of the line is aligned to the patient’s age (x-axis) and severity of initial loss 
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(y-axis); steeply declining lines indicate rapidly progressing eyes. After applying our 
inclusion criteria, 18,414 reference database patients were included. 
 In Figure 4, GMS patients progressing (red lines) and improving (green lines) 
faster than the 90% limit in the reference database with the same number of VFs are 
highlighted. Three (1.9%; 95% CI 0.4 to 5.4 %) patients are flagged as having VF changes 
outside of expected limits.  
Table 1 shows the diagnoses of the 14 patients identified by both analyses as 
having VF MD changes outside the 90% limits of the reference database. Nine patients 
performed worse than patients in the reference database, although five of these had a 
positive MD at their baseline GMS visit. Of the remainder, one patient was judged to be 
progressing by the GMS reviewer, one patient had a retinal arterial occlusion unrelated 
to their glaucoma, one patient was exited from the GMS due to suspected unreliable VF 
performance, and one was deemed stable by the GMS reviewer and kept in the clinic. 
 
 
Figure 1.  Distribution of expected limits for size of difference in MD (dB) index between 
two appointments in the reference database (N = 22,124) based on the patient’s average 
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MD. Areas at the upper and lower most part of the plot (red) show results outside of 90% 
normal limit. The lower most part of the plot indicates worsening VF results. 
 
 
Figure 2. Virtual GMS patient (points) data compared against the reference database. Our 
total sample (N=250) is divided into 3 groups based on average MD. Plot A ranges from -
18.9 dB to ≤ -2.4 dB (83 virtual GMS patients), plot B ranges from >-2.4 dB to ≤-0.8 dB (84 
virtual GMS patients), and plot C includes patients > -0.8 dB (83 virtual GMS patients) 
 
 
Figure 3. Hedgehog plot showing the rate of VF progression in the reference database 
(N=18,414). Three patients have been highlighted. For each patient, a point represents a 
score on the VF test and patients’ age at time of test. A regression line is fitted for each 
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patient using all of the points in their series. Steeply declining lines indicate faster VF 
progression. The blue shaded area denotes likely visual impairment. In this example, 
patient 1 has the most VF tests in their series and shows a faster rate of progression than 
patient 2 or 3. 
 
 
 
Figure 4. Of the 250 virtual GMS patients, 158 (63.2%) had 3 or more VFs in their series. 
These patients are superimposed on the reference dataset Hedgehog Plot. Grey lines 
show rates of progression for patients in the reference database.  Darker lines show 
virtual GMS patients. Red lines highlight the virtual GMS patients outside the 90% limits 
for progression. The green line highlights the virtual GMS patient outside the 90% limits 
for ‘improvement’.  
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Table 1. Outcomes of GMS patients identified as falling outside of the 90% limits in the 
reference database. 
Age 
(years) 
Diagnosis MD at first 
GMS visit 
(dB) 
Progressing 
(P) or 
‘improving’ 
(I) 
GMS outcome recorded in notes 
49 
 
OHT +1.03 P Remains in GMS; 12-month review 
52 
 
OHT -22.59 I Exited GMS in January 2015; noted 
to be poor VF performer; moved to 
consultant clinic for further follow 
up. 
63 
 
OHT -2.60 I Remains in GMS; 9-month review 
65 
 
OHT -2.08 I Remains in GMS; 12-month review 
67 
 
OHT +1.45 P Remains in GMS; 6-month review 
71 
 
OHT +1.56 P Remains in GMS; 12-month review 
75 
 
OHT +0.03 P Remains in GMS; 12-month review 
77 OHT -2.02 P Remains in GMS; 18-month review 
78 
 
OHT -3.24 I Remains in GMS; 12-month review 
42 
 
Glaucoma 
suspect 
+1.55 P Remains in GMS; 12-month review 
55 Glaucoma 
suspect 
-4.17 P Exited GMS April 2016; discharged 
from service- no evidence of 
glaucoma, poor VF performer. 
77 * 
 
Glaucoma 
suspect 
-2.16 P Retinal arterial occlusion; detected 
in March 2016 (i.e. pre-glaucoma 
service visit); glaucoma stable. 
80 
 
Glaucoma 
suspect 
-13.78 I Exited GMS June 2016; no evidence 
of glaucoma, poor VF performer; 
moved to consultant clinic to assess 
suitability for discharge from 
glaucoma service. 
82 POAG -7.97 P Exited GMS April 2016 as evidence 
of progression. Review in 
consultant clinic. 
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Key. MD = mean deviation, GMS = glaucoma monitoring service, OHT = ocular 
hypertension, POAG = primary open angle glaucoma, VF = visual field. 
* shown to be significantly progressing with both analyses 1 & 2  
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Discussion 
  Our study exploited a “big data” approach to investigate whether patients in a 
GMS score similarly on a measure of vision loss (i.e. visual field MD) to patients who 
attend consultant-led appointments (reference database). Our results show the 
difference in MD values between two hospital appointments for patients attending the 
GMS is similar to those in the reference database. 
 Using “big data” we created ranges of expected change in MD over a similar follow 
up interval, using patients with a similar profile to those attending the GMS. Our findings 
also showed that 12 patients in the GMS scored outside the expected range on the VF test. 
The proportion of GMS patients outside the expected range (4.8%) is smaller than the 
10% (25 patients) we allowed for. Similarly, when compared to the reference database, 
there were fewer GMS patients with unusually fast progression. The results of our study 
indicate that the number of patients in a GMS performing better or worse than expected 
on the VF test is smaller than anticipated.  
 The results of our study are relevant to current clinical practice with regard to 
monitoring patients with glaucoma. Our findings suggest that patients attending a GMS 
are no ‘worse-off’ than those attending the standard-care appointments. Specifically, 
when using VF data from a large reference database as benchmarks for expected changes 
in MD score, GMS patients’ VF test results tended to be as expected. In the few cases where 
GMS patients’ MD scores were outside the expected results, further analysis on these 
patients was carried out. It was found that 5 patients scoring outside the expected results 
had been highlighted as ‘improving’. Of the 7 patients showing a worse performance 
compared to the reference database, 3 had been picked up by the GMS reviewer, with the 
remainder being deemed stable. It should be noted that those deemed clinically stable 
had a diagnosis of either ocular hypertension or suspected glaucoma with no significant 
VF defect.  
 A strength of our study is the number of patients we included in our analysis. 
Access to a wealth of VF entries in the reference database, even after applying sensible 
selection criteria, meant that we closely matched patients in the GMS to patients 
attending standard, consultant-led appointments. The total number of patients in the 
reference database for the first part of our analysis was 22,124 and 18,414 for the second 
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part. These large numbers allowed limits for variability to be stratified by disease severity 
(21-23) 
It should be noted that the number of patients in the reference database used to 
create our expected limits is not equal across all average MD bins on the x-axis of our 
plots. For example, the number of reference database patients creating the -15 dB average 
MD limit was 257, whereas the number of patients creating the -5 dB average MD limit 
was 1,350. However, we wished to include as much data as possible and so, given that 
there were simply more patients with average MD of -5 dB than -15 dB, this disparity is 
to be expected. Additionally, the -15 dB limits were where the fewest reference database 
patients were included (N=257), but this number of patients remains substantial. A 
further point to consider is that in Figure 4 it appears older patients have less stable VFs 
in the GMS. This could be due to these patients presenting at a later stage in the disease, 
precipitating more VF variability, or they have had the disease for a longer period of time, 
or they are worse test takers. 
A limitation to our study is the inclusion criteria we used to construct the 
reference data percentiles (Figure 1). We match GMS patients to reference database 
patients using baseline MD, age, and interval between clinic visits. We did not have access 
to reference database patients’ diagnoses. GMS patients are a highly selected sub-group 
of glaucoma patients attending the Moorfields Eye Hospital glaucoma outpatients service; 
some reference database patients would not be suitable for virtual monitoring. For 
example, glaucoma patients with a coexisting ocular comorbidity would not be suitable 
for GMS but may be present in the reference database and this represents a possible 
confounder. Furthermore, we anticipated that patients in the GMS would be experienced 
in performing the VF test. However, some GMS patients appeared to show improvement 
in their MD scores; these patients may be unreliable at performing the VF test or are 
continuing to have perimetric learning effects despite being experienced test-takers. We 
did not have data for variables such as intraocular pressure, or optic nerve assessment 
which may influence progression. This is a key limitation. Further analysis adjusting for 
these factors would be a valuable addition to the literature. Patients in the “big data” 
(reference) group are simply defined as having measurable glaucoma-like VF loss who 
are attending glaucoma clinics. Therefore, for example, we cannot rule out some patients 
having optic neuropathies that produce glaucoma-like VF deficits, but the number would 
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be insignificant given the sheer number of records in the reference database. Moreover, 
for example, patients with sudden onset retinal vein occlusions or unstable aggressive 
glaucoma may skew the expected parameter limits in the reference database. However, 
as the reference database is comprised of patients attending glaucoma clinics, the number 
of those with VF loss due to non-glaucomatous comorbidities is likely to be smaller than 
that reported in general population prevalence estimates. (24) But these examples do 
highlight some limitations of the "big data" approach. A final limitation surrounds the 
method used to assess change between VFs. Here we have used a VF index (MD) and 
alternative methods using all the points in the VF might offer more sensitivity to change. 
(25) 
The average number of appointments for GMS patients in our study was three. 
Further analysis where patients attending a GMS are followed longitudinally may provide 
more information regarding the suitability of virtual monitoring. Given that GMS are a 
relatively new addition to the HES, this idea should be revisited in future research.  
To our knowledge, this is the first study that utilised “big data” to evaluate 
outcomes of patients in a GMS. The utility of pooling large databases together to identify 
trends and also predict future risks to health is recognised elsewhere. (26) In the 
presented study, we have utilised “big data” to assess whether a new model of service 
delivery results in equivalent outcomes to that of the standard out-patient model, and for 
the metric we used (i.e. MD), we found that it did. The digital nature of VF test results 
lends itself to “big data” analysis. Still, the VF result is but one measure of glaucoma status. 
However, we feel that this study has shown the potential of using “big data” in the 
ophthalmology setting to confirm the equivalence of care between a new and standard 
model of service delivery.  
Contributors: LJ: Data analysis, data interpretation, manuscript preparation. SRB: Data 
analysis, data interpretation, manuscript critique. MAM: data analysis, manuscript 
critique. DPC: Study design, data interpretation, manuscript critique. AK: Study design, 
data interpretation, manuscript critique. 
Conflict of interest: The authors declare no conflict of interest. 
 
17 
 
References 
1. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-
adjusted life years (DALYs) for 306 diseases and injuries and healthy life 
expectancy (HALE) for 188 countries, 1990–2013: quantifying the 
epidemiological transition. The Lancet 2015;386:2145-91. 
2. Lewis R, Dixon J. Rethinking management of chronic diseases. Bmj 2004;328: 220-
22.  
3. Department of Health. Using information technology to improve the NHS 
September 2016. https://www.gov.uk/government/publications/using-
information-technology-to-improve-the-nhs (accessed 17 Jan 2017) 
4. Kotecha A, Baldwin A, Brookes J, et al. Experiences with developing and 
implementing a virtual clinic for glaucoma care in an NHS setting. Clinical 
Ophthalmology (Auckland, NZ) 2015;9:1915-23. 
5. Trikha S, Macgregor C, Jeffery M, et al. The Portsmouth-based glaucoma 
refinement scheme: a role for virtual clinics in the future. Eye 2012;26:1288-1294. 
6. Ross P, Alkadhimi G, Aravind P, et al. A pilot study of a nurse delivered virtual 
outpatient clinic for patients with hepatocellular cancer (HCC). European Journal 
of Surgical Oncology 2016;42:249-250. 
7. Vardy J, Jenkins P, Clark K, et al. Effect of a redesigned fracture management 
pathway and ‘virtual’ fracture clinic on ED performance. BMJ Open 2014;4(6), 
p.e005282. 
8. Vernon S, Hillman J, MacNab H, et al. Community optometrist referral of those aged 
65 and over for raised IOP post-NICE: AOP guidance versus joint college 
guidance—an epidemiological model using BEAP. Br J Ophthalmol 2011;95: 1534–
1536. 
9. Edgar D, Romanay T, Lawrenson J, et al. Referral behaviour among optometrists: 
Increase in the number of referrals from optometrists following the publication of 
the April 2009 NICE guidelines for the diagnosis and management of COAG and 
OHT in England and Wales and its implications. Optom Pract 2010;11:33-38. 
10. Khan S, Clarke J, Kotecha A. Comparison of optometrist glaucoma referrals against 
published guidelines. Ophthalmic and Physiological Optics 2012;32:472-477. 
18 
 
11. de Silva S, Riaz Y, Purbrick R, et al. There is a trend for the diagnosis of glaucoma 
to be made at an earlier stage in 2010 compared to 2008 in Oxford, United 
Kingdom. Ophthalmic Physiol Opt 2013;33:179–82.  
12. Rathod D, Win T, Pickering S, et al. Incorporation of a virtual assessment into a 
care pathway for initial glaucoma management: feasibility study. Clinical & 
Experimental Ophthalmology 2008;36:543-46.  
13. Wright H, Diamond J. Service innovation in glaucoma management: using a web-
based electronic patient record to facilitate virtual specialist supervision of a 
shared care glaucoma programme. British Journal of Ophthalmology 
2014;99(3):313-17. 
14. Clarke J, Puertas R, Kotecha A, et al. Virtual clinics in glaucoma care: face-to-face 
versus remote decision-making. British Journal of Ophthalmology 2016; 
doi:10.1136/bjophthalmol-2016-308993. 
15. Kotecha A, Bonstein K, Cable R, et al. Qualitative investigation of patients’ 
experience of a glaucoma virtual clinic in a specialist ophthalmic hospital in 
London, UK. BMJ Open 2015; 5:e009463. doi: 10.1136/bmjopen-2015-009463 
16. Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and 
potential. Health Information Science and Systems 2014;2:3. 
17. Boodhna T, Crabb D. Disease severity in newly diagnosed glaucoma patients with 
visual field loss: trends from more than a decade of data. Ophthalmic and 
Physiological Optics 2015;35:225-230. 
18. Sparrow J, Taylor H, Qureshi K, et al. The cataract national data set electronic 
multi-centre audit of 55 567 operations: case-mix adjusted surgeon’s outcomes 
for posterior capsule rupture. Eye (Lond) 2011;25:1010–15. 
19. Boodhna T, Saunders L, Crabb DP. Are rates of vision loss in patients in English 
glaucoma clinics slowing down over time; Trends from a decade of data. Eye 
2015;29:1613-19. 
20. Russell RA, Crabb DP, Malik R, et al. The relationship between variability and 
sensitivity in large-scale longitudinal visual field data. Invest Ophthalmol Vis Sci 
2012;53(10):5985:90. 
21. Russell RA, Garway-Heath DF, Crabb DP. New insights into measurement 
variability in glaucomatous visual fields from computer modelling. PloS one 
2013;8(12):p.e83595. 
19 
 
22. Chauhan BC, Tompkins JD, LeBlanc RP, et al. Characteristics of frequency-of-seeing 
curves in normal subjects, patients with suspected glaucoma, and patients with 
glaucoma. Investigative Ophthalmology & Visual Science 1993;34(13):3534-40. 
23. Henson DB, Chaudry S, Artes PH, et al. Response variability in the visual field: 
comparison of optic neuritis, glaucoma, ocular hypertension, and normal 
eyes. Investigative Ophthalmology & Visual Science 2000;41(2):417-21. 
24. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion 
in Australia: the Blue Mountains Eye Study. Archives of Ophthalmology 1996; 
114(10):1243-7. 
25. Bryan SR, Vermeer KA, Eilers PH, et al. Robust and Censored Modeling and 
Prediction of Progression in Glaucomatous Visual Fields. Investigative 
Ophthalmology & Visual Science 2013;54(10): 6694-6700. 
26. Bradley PS. Implications of big data analytics on population health 
management. Big Data 2013; 1(3):152-59. 
 
 
 
 
 
 
 
 
